Zinc and Cancer: Implications for LIV-1 in Breast Cancer

Grattan, Bruce J.; Freake, Hedley C.

doi:10.3390/nu4070648

Cited by 98 publications

(105 citation statements)

References 190 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…This protein may play a role in both cell growth, by acting as a zinc transporter, as well as the induction of metastasis, by association with matrix metalloproteinases. 41 It is worth mentioning that this transporter protein is also detected in neoplastic breast tissue.…”

Section: Author(s) Study Design Resultsmentioning

confidence: 99%

Zinc and metalloproteinases 2 and 9: What is their relation with breast cancer?

Holanda

Oliveira²,

Cruz³

et al. 2017

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Zinc is the catalytic component of proteins that regulate responses to DNA damage, intracellular signaling enzymes, and matrix metalloproteinases, which are important proteins in carcinogenesis. The objective of this review is to bring current information on the participation of zinc and matrix metalloproteinases types 2 and 9 in mechanisms involved in the pathogenesis of breast cancer. We conducted a literature review, in consultation with the PubMed, Lilacs, and Scielo databases. The zinc and cysteine residues are structural elements shared by all members of the family of matrix metalloproteinases, and these proteins appear to be involved in the propagation of various types of neoplasms, including breast cancer. Moreover, transported zinc is likely to be used for the metalation of the catalytic domain of the newly synthesized metalloproteinases before the latter are secreted. Accordingly, increase in zinc concentrations in cellular compartments and the reduction of this trace element in the blood of patients with breast cancer appear to alter the activity of metalloproteinases 2 and 9, contributing to the occurrence of malignancy. Thus, it is necessary to carry out further studies with a view to clarify the role of zinc and metalloproteinases 2 and 9 in the pathogenesis of breast cancer.

show abstract

Section: Author(s) Study Design Resultsmentioning

confidence: 99%

Zinc and metalloproteinases 2 and 9: What is their relation with breast cancer?

Holanda

Oliveira²,

Cruz³

et al. 2017

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…In various studies, it was found that the serum levels of trace elements in patients with BC have changed and although their role is not fully understood, it may be associated with the risk of this disease (8). Zinc (Zn) is a vital mineral for the operation of numerous cellular processes and growth and may play an important role in malignancy etiology and outcome (9). This mineral has an excessive accumulation in BCs and malignant cell lines compared with normal mammary epithelium (10).…”

Section: Introductionmentioning

confidence: 99%

Serum Levels of Selenium and Zinc in Patients with Breast Cancer: A Case-Control Study

et al. 2017

View full text Add to dashboard Cite

Background: Zinc (Zn) and Selenium (Se) are trace minerals that have high anti-cancer and chemopreventive properties. Objectives: This study aimed at evaluating the serum levels of both elements in women with breast cancer (BC) compared with control group and the correlation of them with risk factors of BC. Methods: In a case-control study, 142 women with BC and 158 healthy controls, aged 19 to 88 years, were selected. Both groups did not use any type of supplement 3 months before participation in the study; there was no history of chronic kidney or liver disease or malabsorption disorders among the participants and body mass index was between 18.5 and 30 based on Quetelet index. The Se by graphite furnace and Zn by flame were atomized and the amount of each of 2 elements was measured and recorded by the Absorption device.

show abstract

“…In spite of applying The animals' body weight in particular weeks of the experiment are presented in Table 2. Carcinogen treatment did not result in any loss of appetite of the animals, which is evidenced by a greater increase in body weight (week [7][8][9][10][11][12][13][14][15][16][17][18][19] in the group that obtained Cu plus resveratrol (p < 0.001), and no differences in body weight observed in the remaining supplemented groups; increases in body weight were significantly lower in rats fed standard diet (unsupplemented group), as compared with the non-DMBAtreated group (p < 0.005) (Table 3). However, no weight loss was found in the rats of any of the examined groups (Tables 2, 3).…”

Section: Resultsmentioning

confidence: 99%